Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is a pioneering advanced ceramics company, renowned for its development and production of medical-grade silicon nitride. This innovative biomaterial is not only ideal for spinal fusion applications but also boasts a variety of medical uses due to its unique nanosurface texture. This texture promotes bone growth, offers excellent imaging capabilities, and demonstrates antibacterial properties.
Originally known for its research, development, and commercialization of silicon nitride-based medical devices, SINTX has expanded its horizons. Today, the company is involved in a wide array of biomedical, technical, and antipathogenic applications. SINTX's biomedical products are celebrated for their biocompatibility, bioactivity, and exceptional bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in patients across the United States, Europe, Brazil, and Taiwan.
SINTX Technologies operates the only FDA-registered and ISO 13485 certified silicon nitride medical device manufacturing facility in the world. Their robust sales and distribution network underpins their commitment to delivering innovative healthcare solutions that significantly enhance patient quality of life.
In addition to medical devices, SINTX is actively engaged in developing solutions for various technical and antipathogenic applications. These efforts include the creation of advanced ceramic materials designed to meet the evolving needs of multiple industries.
- Core Business: Manufacturing of medical-grade silicon nitride and advanced ceramics for diverse applications.
- Recent Achievements: Successful implantation of silicon nitride spinal implants in multiple countries.
- Current Projects: Expansion into technical and antipathogenic ceramic solutions.
- Partnerships: Collaborations with healthcare providers and research institutions globally.
- Financial Condition: Continuously innovating to maintain a strong market presence and financial stability.
Stay updated with the latest news from SINTX Technologies, as they continue to push the boundaries of advanced ceramics and medical innovation.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the filing of its 2021 Annual Report on Form 10-K with the SEC. The company has made significant investments in 2021 to expand its biomedical, industrial/armor, and antipathogenic business segments, focusing on revenue-generating opportunities, including armor materials and biomedical implants. A conference call is scheduled for April 13, 2022, to update stakeholders. SINTX manufactures advanced ceramics at its facilities in Salt Lake City, Utah, and is dedicated to developing advanced material-based solutions.
SINTX Technologies announced a $300k Phase 1 grant from the National Institutes of Health to develop 3D printed silicon nitride and polyetherketoneketone implants for craniomaxillofacial surgery. This collaboration with Drexel University and others aims to enhance implant performance by reducing failure rates linked to infections and poor integration. Over 235,000 CMF surgeries occur annually in the U.S. with a 5.5% failure rate. The grant supports the commercialization of this innovative material that could significantly improve patient outcomes.
SINTX Technologies, Inc. (NASDAQ: SINT) announced advancements in manufacturing technologies for fabrics impregnated with silicon nitride, highlighting successful antipathogenic testing results. Recent tests showed that the embedded fabric effectively inactivated Staphylococcus Aureus and SARS-CoV-2, indicating enhanced antiviral properties. These developments reinforce SINTX's collaboration with a private European firm and mark significant milestones in the production of antipathogenic fabrics for various applications, including medical gowns and facemasks.
SINTX Technologies, Inc. (NASDAQ: SINT) announces the retirement of Chief Scientific Officer Dr. Bryan J. McEntire after 17 years. Dr. Ryan Bock, currently Director of R&D, will step in as Vice President of R&D, leading ongoing biomaterial development and expanding research on antipathogenic ceramics. Dr. McEntire has made significant contributions to the company, including research and product development for orthopedic implants made from silicon nitride. He will remain connected to SINTX in an advisory role.
SINTX Technologies recently provided a year-end business update, highlighting advancements in its biomedical, antipathogenic, and industrial segments. The company initiated joint research with leading universities under an NIH grant to develop 3D-printed silicon nitride PEEK composite spinal implants. New patent protections for antipathogenic applications offer potential commercial opportunities. Additionally, SINTX is constructing updates to its manufacturing facility for full production. Notably, the company received full forgiveness of a $509,148 SBA PPP loan, strengthening its financial position.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the launch of its subsidiary SINTX Armor, signing a 10-year lease for a facility in Salt Lake City for development and manufacturing. The facility will house equipment moved from Dayton, OH, with construction updates underway to facilitate machine qualification starting December 2021. The new facility will produce advanced ceramic armor, including BoroShock and DuraShock, aimed at military and industrial applications. Revenue growth is anticipated in H2 2022 as production begins.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the termination of its Patent License Agreement with O2TODAY due to delays in product development.
This follows SINTX's previous evaluation of joint efforts with O2TODAY, emphasizing its commitment to developing antiviral and antimicrobial fabrics using SINTX's patented FleX SN-AP silicon nitride powder. SINTX continues to pursue collaborations and product development in the antipathogenic fabric space, vital to its business strategy.
SINTX Technologies reported preliminary Q3 2021 revenue of approximately $240k, surpassing Q1 and Q2 revenues. Revenue stems from three sectors: spinal implants, antipathogenic fabrics, and armor. The company anticipates new revenue in Q4 2021 from open prototype orders for aerospace components and industrial applications. SINTX is focused on expanding its presence in advanced ceramics manufacturing at its FDA and ISO certified facility. A detailed business update will follow the upcoming Quarterly Report on Form 10-Q.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the shipment of production quantities of a new porous, laser-textured monolithic silicon nitride implant for surgical spinal solutions. This shipment follows successful collaboration with CTL Amedica and supports a product launch expected in Q4 2021. The implants aim to enhance osseointegrative and antibacterial properties. SINTX has also submitted a provisional patent for improved manufacturing methods, supported by a Phase 1 grant from NIH. The company is actively investing in advanced manufacturing technologies and workforce recruitment.
SINTX Technologies has been awarded a $308,301 Phase 1 grant by the NIH to develop a 3-D printed silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This research focuses on enhancing the antibacterial and osseointegrative properties of silicon nitride. The project aims to capitalize on existing PEEK implant technology while integrating novel characteristics. Collaborating with notable universities, SINTX is positioned to advance spinal implant technology and plans to pursue a Phase 2 grant upon completion of this project.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
What does SINTX Technologies, Inc. specialize in?
What are the key features of SINTX's silicon nitride products?
Where have SINTX's spinal implants been successfully implanted?
Is SINTX Technologies FDA registered?
What other applications is SINTX involved in?
How does SINTX's silicon nitride benefit medical applications?
What are the recent achievements of SINTX Technologies?
Who can benefit from SINTX's products?
How does SINTX contribute to healthcare innovation?
Where can I find the latest news about SINTX Technologies?
